Published in Eur J Neurosci on March 01, 2006
Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci (2009) 5.53
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Neuroimmune interactions and pain: focus on glial-modulating targets. Curr Opin Investig Drugs (2008) 1.50
Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. Eur J Neurosci (2010) 1.50
Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology (2008) 1.39
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics (2009) 1.36
Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol (2007) 1.34
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol (2010) 1.33
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol (2006) 1.32
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008) 1.28
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci (2012) 1.27
Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther (2007) 1.26
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci (2014) 1.25
Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol (2007) 1.24
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol (2011) 1.20
Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. Mol Pain (2009) 1.17
Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol (2007) 1.15
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci (2008) 1.12
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther (2008) 1.10
Validating Antibodies to the Cannabinoid CB2 Receptor: Antibody Sensitivity Is Not Evidence of Antibody Specificity. J Histochem Cytochem (2014) 1.09
MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol (2008) 1.05
Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci (2008) 1.04
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci (2010) 1.04
Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol (2012) 1.02
The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol (2012) 1.01
Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol (2011) 1.00
Actions of N-arachidonyl-glycine in a rat inflammatory pain model. Mol Pain (2007) 0.98
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol (2010) 0.98
Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol (2009) 0.96
Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol Pain (2009) 0.93
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav (2011) 0.93
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets (2008) 0.92
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol (2007) 0.90
Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. Future Med Chem (2012) 0.90
Bilateral changes of cannabinoid receptor type 2 protein and mRNA in the dorsal root ganglia of a rat neuropathic pain model. J Histochem Cytochem (2013) 0.90
Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res (2009) 0.90
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav (2012) 0.90
Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg (2012) 0.89
Metabolomics uncovers dietary omega-3 fatty acid-derived metabolites implicated in anti-nociceptive responses after experimental spinal cord injury. Neuroscience (2013) 0.89
2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. ChemMedChem (2009) 0.88
Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. AAPS J (2010) 0.87
Modulating the delicate glial-neuronal interactions in neuropathic pain: promises and potential caveats. Neurosci Biobehav Rev (2014) 0.86
Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain (2014) 0.86
Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.84
Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One (2012) 0.83
Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis. J Urol (2013) 0.82
Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats. Addict Biol (2016) 0.82
The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J (2013) 0.81
Activation of cannabinoid receptor 2 inhibits experimental cystitis. Am J Physiol Regul Integr Comp Physiol (2013) 0.81
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
Contributions of academic laboratories to the discovery and development of chemical biology tools. J Med Chem (2013) 0.81
Cannabinoid receptors are widely expressed in goldfish: molecular cloning of a CB2-like receptor and evaluation of CB1 and CB2 mRNA expression profiles in different organs. Fish Physiol Biochem (2013) 0.80
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol Neurodegener (2015) 0.79
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology (2017) 0.78
Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci (2012) 0.78
Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy. Neuropharmacology (2014) 0.77
Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br J Pharmacol (2007) 0.77
Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neurosci Lett (2015) 0.76
Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity. Br J Pharmacol (2007) 0.76
Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain. J Neurosci (2017) 0.76
Effects of cannabinoids on caffeine contractures in slow and fast skeletal muscle fibers of the frog. J Membr Biol (2009) 0.76
Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) (2010) 0.76
Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cells. Bioorg Med Chem Lett (2011) 0.76
Alterations in the anandamide metabolism in the development of neuropathic pain. Biomed Res Int (2014) 0.76
The cannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice. J Pharmacol Exp Ther (2017) 0.75
The Role of Cannabinoid Receptors in the Descending Modulation of Pain. Pharmaceuticals (Basel) (2010) 0.75
Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress. Cancers (Basel) (2010) 0.75
Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature (1994) 3.33
The beta3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterol Motil (2008) 1.44
Endoplasmic reticulum, Bcl-2 and Ca2+ handling in apoptosis. Cell Calcium (2003) 1.42
Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. Dig Liver Dis (2009) 1.39
Expression pattern of the Tbr2 (Eomesodermin) gene during mouse and chick brain development. Mech Dev (1999) 1.39
In silico research in drug discovery. Trends Pharmacol Sci (2001) 1.36
The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene (2012) 1.34
The 18 kDa translocator protein (TSPO): a new perspective in mitochondrial biology. Curr Mol Med (2012) 1.09
M-15: high-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. Proc Natl Acad Sci U S A (1991) 1.05
Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy. Maturitas (2005) 1.03
IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. Cell Death Differ (2013) 1.02
N-terminal galanin-(1-16) fragment is an agonist at the hippocampal galanin receptor. Proc Natl Acad Sci U S A (1989) 1.00
Pelvic ultrasonography in premenarcheal girls: relation to puberty and sex hormone concentrations. Arch Dis Child (1985) 0.97
Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol (2009) 0.97
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer (2005) 0.96
Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol (2009) 0.96
Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut (2005) 0.95
The microvascular system in ischemic cortical lesions. Acta Neuropathol (1996) 0.94
The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner. Br J Pharmacol (2013) 0.93
HtrA2 deficiency causes mitochondrial uncoupling through the F₁F₀-ATP synthase and consequent ATP depletion. Cell Death Dis (2012) 0.93
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci (2003) 0.92
Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier. Br J Pharmacol (2012) 0.92
Molecular characterization of human healthy and neoplastic cerebral and renal tissues by in vitro (1)H NMR spectroscopy (review). Int J Mol Med (2002) 0.91
Presence and physical state of HPV DNA in prostate and urinary-tract tissues. Int J Cancer (1992) 0.91
Mortality from liver disease among Italian vinyl chloride monomer/polyvinyl chloride manufacturers. Am J Ind Med (1990) 0.91
Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. J Urol (1989) 0.90
Decrease of brain acetylcholine release in aging freely-moving rats detected by microdialysis. Neurobiol Aging (1988) 0.90
The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol (1997) 0.90
Effects of the metabotropic glutamate receptor antagonist MCPG on spatial and context-specific learning. Neuropharmacology (1996) 0.90
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol (2001) 0.89
Systemic interleukin 10 administration inhibits brain tumor necrosis factor production in mice. Eur J Pharmacol (1997) 0.88
Immunohistochemical demonstration of the small GTPase RhoA on epoxy-resin embedded sections. Micron (2004) 0.88
Acute arthritis during isotretinoin treatment for acne conglobata. Dermatology (1997) 0.87
Qualitative and quantitative analysis of the progressive cerebral damage after middle cerebral artery occlusion in mice. Brain Res (1993) 0.87
The homozygous deletion of the 3' enhancer of the SHOX gene causes Langer mesomelic dysplasia. Clin Genet (2007) 0.87
Serotonergic facilitation of acetylcholine release in vivo from rat dorsal hippocampus via serotonin 5-HT3 receptors. J Neurochem (1994) 0.87
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. J Med Chem (2000) 0.86
[The mortality among the makers of vinyl chloride in Italy]. Med Lav (1992) 0.86
1H-NMR and 13C-NMR lipid profiles of human renal tissues. Biopolymers (2003) 0.86
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res (1998) 0.86
Adenosine A2A receptors and neuroprotection. Ann N Y Acad Sci (1997) 0.86
Listening to speech recruits specific tongue motor synergies as revealed by transcranial magnetic stimulation and tissue-Doppler ultrasound imaging. Philos Trans R Soc Lond B Biol Sci (2014) 0.86
PK11195 inhibits mitophagy targeting the F1Fo-ATPsynthase in Bcl-2 knock-down cells. Curr Mol Med (2012) 0.85
Studies on the antinociceptive effect of [Nphe1]nociceptin(1-13)NH2 in mice. Neurosci Lett (2001) 0.84
Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol (1994) 0.84
Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J Med Chem (1997) 0.84
[Development after metamorphosis of immunologic competence between cutaneous homografts in Xenopus leavis Daudin]. C R Acad Sci Hebd Seances Acad Sci D (1969) 0.84
Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination. Cancer (2001) 0.84
Dopamine metabolism and receptor function after acute and chronic ethanol. J Neurochem (1980) 0.84
Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur J Pharmacol (1995) 0.84
Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study. Climacteric (2005) 0.83
Electrophysiological characterization of vagal afferents relevant to mucosal nociception in the rat upper oesophagus. J Physiol (2007) 0.83
The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats. Brain Res (2001) 0.83
Regulation of synaptic plasticity by mGluR1 studied in vivo in mGluR1 mutant mice. Brain Res (1997) 0.83
Cholesteryl esters in human malignant neoplasms. Int J Mol Med (2003) 0.82
Pertussis toxin-sensitive G-protein mediates galanin's inhibition of scopolamine-evoked acetylcholine release in vivo and carbachol-stimulated phosphoinositide turnover in rat ventral hippocampus. Neurosci Lett (1991) 0.82
Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Cancer Chemother Pharmacol (1990) 0.81
Magnetic resonance spectroscopy and chromatographic methods identify altered lipid composition in human renal neoplasms. Int J Mol Med (2004) 0.81
Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A. J Pharmacol Exp Ther (1999) 0.81
[On the mechanism of the mucolytic action of N-acetyl-L-cysteine]. Boll Soc Ital Biol Sper (1965) 0.81
Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology (Berl) (1990) 0.80
Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. Eur J Cancer Clin Oncol (1988) 0.80
A cohort study on vinyl chloride manufacturers in Italy: study design and preliminary results. Cancer Lett (1987) 0.80
Albumin uptake in OK cells exposed to rotenone: a model for studying the effects of mitochondrial dysfunction on endocytosis in the proximal tubule? Nephron Physiol (2010) 0.80
[Respiratory functional changes in subjects exposed to chromium. I. Spirographic changes]. Lav Um (1973) 0.80
Nationwide pseudo-outbreak of Salmonella enterica ssp. diarizonae, France. Clin Microbiol Infect (2010) 0.80
Transfected Go1 alpha inhibits the calcium dependence of beta-adrenergic stimulated cAMP accumulation in C6 glioma cells. J Biol Chem (1993) 0.79
Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur J Pharmacol (1992) 0.79
Domoic acid toxicity in rats and mice after intracerebroventricular administration: comparison with excitatory amino acid agonists. Pharmacol Toxicol (1992) 0.79
Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur J Pharmacol (1999) 0.79
N-terminal galanin fragments inhibit the hippocampal release of acetylcholine in vivo. Brain Res (1993) 0.79
Renal cell cultures for the study of growth factor interactions underlying kidney organogenesis. In Vitro Cell Dev Biol Anim (2001) 0.79
Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. Br J Pharmacol (2014) 0.78
Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol (1994) 0.78
The FLUKA code: new developments and application to 1 GeV/n iron beams. Adv Space Res (2005) 0.78
In vitro morpho-functional analysis of pancreatic islets isolated from the domestic chicken. Tissue Cell (1993) 0.78
The penetration of roxithromycin into human skin. J Antimicrob Chemother (1990) 0.78
Effects of cholecystokinin peptides and GV 150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices. J Neurochem (1999) 0.78
Quantitation of fetal DNA in maternal serum during the first trimester of pregnancy by the use of a DAZ repetitive probe. Mol Hum Reprod (2006) 0.78
Effects of the l isomer of fenfluramine on dopamine mechanisms in rat brain: further studies. Eur J Pharmacol (1989) 0.77
A morphological study of the expression of the small G protein RhoA in resting and activated MDCK cells. Cell Mol Life Sci (2000) 0.77
The FLUKA code for space applications: recent developments. Adv Space Res (2004) 0.77
Axillary versus peripheral blood levels of sialic acid, ferritin, and CEA in patients with breast cancer. Breast Cancer Res Treat (1990) 0.77
Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report. Transplant Proc (2008) 0.77
Expression of multidrug resistance (mdr) gene(s) in primary lymphoid organs of chicken immune system during embryonic development. Experientia (1995) 0.77
Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands. Expert Opin Investig Drugs (2000) 0.77
Effect of inhibition of neuropeptidases on the pain threshold of mice and rats. Neuropharmacology (1983) 0.77
Acute and chronic ethanol administration on specific 3H-GABA binding in different rat brain areas. Psychopharmacology (Berl) (1980) 0.77
Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNFα treatment. G Ital Dermatol Venereol (2013) 0.77
Involvement of monoaminergic and peptidergic components in cathinone-induced analgesia. Eur J Pharmacol (1985) 0.77
AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. Cell Death Differ (2015) 0.77
Pulmonary hypertension as a predictor of postoperative complications and mortality after liver transplantation. Transplant Proc (2010) 0.77
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemother Pharmacol (1992) 0.77
The neuroprotective glycine receptor antagonist GV150526 does not produce neuronal vacuolization or cognitive deficits in rats. Eur J Pharmacol (1999) 0.77
Cholinergic neurons of the pontomesencephalic tegmentum release acetylcholine in the basal nuclear complex of freely moving rats. Neuroscience (1990) 0.77
Effect of bestatin and thiorphan on [Met5]enkephalin-Arg6-Phe7-induced analgesia. Eur J Pharmacol (1984) 0.76
Nociceptin attenuates opioid and gamma-aminobutyric acid(B) receptor-mediated analgesia in the mouse tail-flick assay. Neurosci Lett (2000) 0.76
Can voltammetry measure nitrogen monoxide (NO) and/or nitrites? J Neurosci Methods (2001) 0.76